Comparison of mRNA and lentiviral based transfection of natural killer cells with chimeric antigen receptors recognizing lymphoid antigens

被引:134
作者
Boissel, Laurent [1 ]
Betancur, Monica [1 ]
Lu, Weiquan [1 ,2 ]
Wels, Winfried S. [4 ]
Marino, Teresa [3 ]
Van Etten, Richard A. [1 ,2 ]
Klingemann, Hans [1 ,2 ]
机构
[1] Tufts Med Ctr, Mol Oncol Res Inst, Boston, MA 02111 USA
[2] Tufts Med Ctr, Div Hematol Oncol, Boston, MA 02111 USA
[3] Tufts Med Ctr, Div Maternal Fetal Med, Dept Obstet & Gynecol, Boston, MA 02111 USA
[4] Chemotherapeut Forschungsinst Georg Speyer Haus, Frankfurt, Germany
关键词
CAR; lymphoid malignancies; lentiviral vector; NK cells; NK-92; EX-VIVO EXPANSION; NK CELLS; CYTOTOXIC ACTIVITY; CYTOLYTIC ACTIVITY; LINE NK-92; LEUKEMIA; CANCER; IMMUNOTHERAPY; MECHANISMS; EXPRESSION;
D O I
10.3109/10428194.2011.634048
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
Natural killer (NK) cells can be engineered to kill resistant B-lymphoid cell lines and primary B-cell chronic lymphocytic leukemia (B-CLL) cells after transfection with chimeric antigen receptors (CARs) recognizing CD19 or CD20. Here we compared mRNA electroporation with lentiviral vector (LV) transduction for both CARs. Transfection efficiency and cytotoxicity of previously NK-92 resistant CLL cells were significantly higher after mRNA electroporation than after LV transduction. Further cell sorting of LV-transduced NK-92 cells resulted in a highly enriched population of transduced cells with significant target cell lysis. Compared to NK-92 cells, peripheral blood and cord blood cells consistently showed < 10% transfection efficiency with mRNA, while LV transduction varied between 8 and 16% for peripheral blood and 12 and 73% for cord blood. These results suggest that LV should be used to achieve sufficient transgene expression if blood NK cells are considered for CAR transduction. Transfection with mRNA results in clinically relevant levels of transfection only in NK-92 cells.
引用
收藏
页码:958 / 965
页数:8
相关论文
共 40 条
[1]
Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial [J].
Arai, S. ;
Meagher, R. ;
Swearingen, M. ;
Myint, H. ;
Rich, E. ;
Martinson, J. ;
Klingemann, H. .
CYTOTHERAPY, 2008, 10 (06) :625-632
[2]
Ex-vivo expansion of NK cells: What is the priority - high yield or high purity? [J].
Berg, Maria ;
Childs, Richard .
CYTOTHERAPY, 2010, 12 (08) :969-970
[3]
Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells [J].
Berg, Maria ;
Lundqvist, Andreas ;
McCoy, Philip, Jr. ;
Samsel, Leigh ;
Fan, Yong ;
Tawab, Abdul ;
Childs, Richard .
CYTOTHERAPY, 2009, 11 (03) :341-355
[4]
Adoptive immunotherapy for cancer: the next generation of gene-engineered immune cells [J].
Berry, L. J. ;
Moeller, M. ;
Darcy, P. K. .
TISSUE ANTIGENS, 2009, 74 (04) :277-289
[5]
Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells [J].
Boissel, Laurent ;
Tuncer, Hande H. ;
Betancur, Monica ;
Wolfberg, Adam ;
Klingemann, Hans .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2008, 14 (09) :1031-1038
[6]
Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells [J].
Boissel, Laurent ;
Betancura, Monica ;
Wels, Winfried S. ;
Tuncer, Hande ;
Klingemann, Hans .
LEUKEMIA RESEARCH, 2009, 33 (09) :1255-1259
[7]
Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations [J].
Campbell, Kerry S. ;
Purdy, Amanda K. .
IMMUNOLOGY, 2011, 132 (03) :315-325
[8]
Monoclonal antibody therapy of chronic lymphocytic leukaemia [J].
Cheson, Bruce D. .
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, 2010, 23 (01) :133-143
[9]
Morphologically typical and atypical B-cell chronic lymphocytic leukemias display a different pattern of surface antigenic density [J].
D'Arena, G ;
Dell 'Olio, M ;
Musto, P ;
Cascavilla, N ;
Perla, G ;
Savino, L ;
Greco, MM .
LEUKEMIA & LYMPHOMA, 2001, 42 (04) :649-654
[10]
D'Costa J, 2009, CURR OPIN MOL THER, V11, P554